1. Home
  2. RYTM vs BE Comparison

RYTM vs BE Comparison

Compare RYTM & BE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • BE
  • Stock Information
  • Founded
  • RYTM 2008
  • BE 2001
  • Country
  • RYTM United States
  • BE United States
  • Employees
  • RYTM 283
  • BE N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • BE Industrial Machinery/Components
  • Sector
  • RYTM Health Care
  • BE Energy
  • Exchange
  • RYTM Nasdaq
  • BE Nasdaq
  • Market Cap
  • RYTM 6.9B
  • BE 5.1B
  • IPO Year
  • RYTM 2017
  • BE 2018
  • Fundamental
  • Price
  • RYTM $102.12
  • BE $57.08
  • Analyst Decision
  • RYTM Strong Buy
  • BE Buy
  • Analyst Count
  • RYTM 13
  • BE 17
  • Target Price
  • RYTM $101.92
  • BE $29.26
  • AVG Volume (30 Days)
  • RYTM 550.8K
  • BE 10.4M
  • Earning Date
  • RYTM 11-04-2025
  • BE 07-31-2025
  • Dividend Yield
  • RYTM N/A
  • BE N/A
  • EPS Growth
  • RYTM N/A
  • BE N/A
  • EPS
  • RYTM N/A
  • BE 0.10
  • Revenue
  • RYTM $156,287,000.00
  • BE $1,630,054,000.00
  • Revenue This Year
  • RYTM $44.69
  • BE $22.74
  • Revenue Next Year
  • RYTM $63.53
  • BE $21.12
  • P/E Ratio
  • RYTM N/A
  • BE $554.53
  • Revenue Growth
  • RYTM 53.55
  • BE 22.72
  • 52 Week Low
  • RYTM $45.91
  • BE $9.02
  • 52 Week High
  • RYTM $106.52
  • BE $57.33
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 60.62
  • BE 77.23
  • Support Level
  • RYTM $101.45
  • BE $48.87
  • Resistance Level
  • RYTM $106.52
  • BE $55.07
  • Average True Range (ATR)
  • RYTM 3.12
  • BE 2.95
  • MACD
  • RYTM -0.43
  • BE 0.29
  • Stochastic Oscillator
  • RYTM 65.84
  • BE 98.63

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About BE Bloom Energy Corporation

Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and internationally.

Share on Social Networks: